Expiratory randomized phase II trial for optimizing treatment dose and duration of adjuvant S-1 plus oxaliplatin in patients with stage III colon cancer
- Conditions
- colon cancer
- Registration Number
- JPRN-UMIN000013825
- Lead Sponsor
- Yokohama City University Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 163
Not provided
1) Tumor located below the peritoneum. 2) history of another malignancy within 5 years 3) Severe postoperattive complication (such as severe infection, severe anastomoitc leakage, intestinal bleeding) 4) Severe concurrent disease such as poorly controlled hypertension, poorly controlled diabetes, interstitial pneumonia or pulmonary fibrosis, severe chronic pulmonary emphysema, heart failure, renal failure, hepatic failure. 5) Severe sensory disorder 6) Severe diarrhea 7) history of severe drug hypersensitivity 8) administration of flucytosine 9) Pregnant females, possibly pregnant females, females wishing to become pregnant and nursing mothers. Males who are currently attempting to produce a pregnancy 10) Severe psychiatric disorder 11) Physician concludes that the patient's participation in this trial is inappropriate.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method